New York, 26 January 2022
Eurazeo, through its Mid-Large Buyout strategy, today announced it has acquired a majority stake
in Cranial Technologies, the market leader in treating infant plagiocephaly (commonly known as
“Flat Head Syndrome”). Eurazeo is investing over $200 million alongside an equity rollover from
the existing management team.

Founded in 1986, Cranial Technologies is the leading treatment provider and manufacturer of
helmets used for treating infants with various forms of plagiocephaly, brachycephaly and
scaphocephaly. Plagiocephaly is a common condition that affects nearly half of all babies born
each year. To date, Cranial Technologies has cared for over 300,000 babies using its FDA-approved
DOC Band® cranial orthotic. The Company delivers its helmets through 80 locations based in the
US, which it operates to treat patients directly, in addition to six licensed clinics internationally.
Eurazeo’s investment will support Cranial Technologies’ expansion across the US and other key
international markets by increasing awareness and expanding its clinical locations, in addition to
extending its product offerings into complementary business lines. Its strong pediatrician referral
network and custom manufacturing capabilities are solid strategic assets for Cranial Technologies’
development.

Marc Frappier, Member of the Executive Board, Managing Partner of Mid-Large Buyout, commented:
“We are delighted to announce the acquisition of Cranial Technologies, the fifth investment
for Eurazeo’s Mid-Large buyout strategy in the US. We are proud to be the partner of choice
for mid-sized companies with strong development ambitions. With Eurazeo, Cranial
Technologies will benefit from a deep healthcare expertise, a team of committed experts,
a global network and financial resources.”

Eric Sondag, Managing Director, Eurazeo, Mid-Large Buyout stated:
“Cranial Technologies is an industry leader that has pioneered a solution for a common
condition for infants, ensuring they reach their early development milestones
successfully. Debbie and her team have built a business centered on delivering superior
outcomes for patients and their families, which is evident in their customer satisfaction
metrics and loyalty with prescribing physicians. We’re pleased to partner with Debbie and
the rest of the management team to raise awareness of plagiocephaly and bring Cranial
Technologies’ outstanding products and top-rated care to growing families.”

Debbie James, CEO of Cranial Technologies, said:
“Since Cranial Technologies was founded over 30 years ago, our mission has been to
provide the best possible treatment, experience and outcome for every family who seeks
our care. We are excited to work with Eurazeo, a partner not only with an impressive track
record in scaling companies, but one who believes in our mission alongside our team.
Together, we look forward to welcoming new families around the world to our clinics. “

EURAZEO’S DEEP HEALTHCARE EXPERTISE PROVIDES LAUNCHPAD FOR INTERNATIONAL
GROWTH
With over 12% of private equity assets under management invested in the Healthcare sector,
Eurazeo provides deep industry expertise alongside financial and human capital to help mediumsized
Healthcare companies realize their growth potential.
Eurazeo’s Healthcare portfolio includes, in particular, DORC, a leading producer of opthalmic
surgery instruments and equipment, and Peters Surgical, manufacturer of single-use sterilized
surgical devices, in addition to multiple Digital Health and Biotech companies, all pursuing
increased digitization and global expansion in partnership with Eurazeo.
In addition, Eurazeo holds a majority stake in Kurma Partners, a French venture capital firm
specializing in biotechnology and medical innovation, and manages the Nov Santé fund on behalf
of the French Insurance Federation (FFA) and Caisse des Dépôts, created to accelerate the
digitization of the French healthcare industry.

ABOUT EURAZEO
 Eurazeo is a leading global investment company, with a diversified portfolio of €27 billion in
assets under management, including nearly €19.2 billion from third parties, invested in
450 companies. With its considerable private equity, venture capital, private debt as well as
real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes,
supporting their development through the commitment of its nearly 300 professionals and
by offering deep sector expertise, a gateway to global markets, and a responsible and stable
foothold for transformational growth. Its solid institutional and family shareholder base,
robust financial structure free of structural debt, and flexible investment horizon enable
Eurazeo to support its companies over the long term.
 Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, Singapore, London,
Luxembourg, Frankfurt, Berlin, Milan and Madrid.
 Eurazeo is listed on Euronext Paris.
 ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

ABOUT CRANIAL TECHNOLOGIES
 Founded in 1986, Cranial Technologies has provided plagiocephaly treatment to over 300,000
babies in 80 U.S. treatment centers. Our mission is to provide the best possible treatment,
experience and outcome for every family who seeks our care. Cranial Technologies invented
the DOC Band®, the first FDA-cleared cranial orthotic, and the DSi® (Digital Surface Imaging)
system. For more information, visit : www.cranialtech.com.

EURAZEO CONTACT
Virginie Christnacht
HEAD OF COMMUNICATIONS
vchristnacht@eurazeo.com
+33 (0)1 44 15 76 44
Pierre Bernardin
HEAD OF INVESTOR RELATIONS
pbernardin@eurazeo.com
+33 (0)1 44 15 16 76
PRESS CONTACT
Julia Fisher
EDELMAN
Julia.Fisher@edelman.com
+1 646 301 2968